Crossmark

Plasma p-tau217, quantified by the fully automated LUMIPULSE G platform, outperforms p-tau181 in predicting amyloid pathology in cognitive complaints patients

Crossref DOI link: https://doi.org/10.1038/s41598-025-34241-7

Published Online: 2026-01-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Silva-Spínola, Anuschka

Durães, João

de Oliveira, João Pedro Guedes

Tábuas-Pereira, Miguel

Lima, Marisa

de Mendonça, Alexandre

Santana, Isabel

Baldeiras, Inês
Funding

Funding for this research was provided by:

Universidade de Coimbra (PT0056.A.02)

Fundação para a Ciência e a Tecnologia (EXPL/MEC-NEU/0192/2021)

Biogen
License Information

Text and Data Mining valid from 2026-01-15

Version of Record valid from 2026-01-30
More Information

Article History

Received: 10 October 2025

Accepted: 26 December 2025

First Online: 15 January 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below